Patents Assigned to Intradigm Corporation
-
Publication number: 20120115923Abstract: This invention describes compositions and methods using siRNA to target various genes expressed in cells of injured tissue during scar formation to promote scar-free wound healing.Type: ApplicationFiled: December 29, 2006Publication date: May 10, 2012Applicant: Intradigm CorporationInventors: Wei-Wu He, Patrick Y. Lu
-
Publication number: 20110282093Abstract: The invention relates to heterobifunctional polyethylene glycol reagents, methods of producing them and methods of using them.Type: ApplicationFiled: November 12, 2008Publication date: November 17, 2011Applicant: Intradigm CorporationInventors: Daniel E. Levy, Samuel Zalipsky, Steven M. Chamow
-
Publication number: 20110046067Abstract: The present invention provides nucleic acid molecules that inhibit EGFR expression. Methods of using the nucleic acid molecules are also provided.Type: ApplicationFiled: June 20, 2008Publication date: February 24, 2011Applicant: Intradigm CorporationInventors: Xiaodong Yang, Frank Y. Xie, Yijia Liu, Ying Liu
-
Patent number: 7893244Abstract: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.Type: GrantFiled: February 8, 2008Date of Patent: February 22, 2011Assignee: Intradigm CorporationInventors: Yijia Liu, Patrick Y. Lu, Martin C. Woodle, Frank Y. Xie
-
Patent number: 7893243Abstract: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.Type: GrantFiled: June 29, 2007Date of Patent: February 22, 2011Assignee: Intradigm CorporationInventors: Yijia Liu, Patrick Y. Lu, Martin C. Woodle, Frank Y. Xie
-
Publication number: 20110038849Abstract: Compositions and methods for treating diseases, such as cancers. The compositions are effective to silence, down-regulate or suppress the expression of a validated target gene by stimulating the process of RNA interference of gene expression, thus inhibiting tumor growth. The invention also provides methods for treating diseases, such as cancers, by inactivation of a validated target gene product, using neutralizing antibody or small molecule drug, to inhibit tumor growth. More particularly, the compositions and methods are directed toward a cancer or a precancerous growth in a mammal, associated with pathological expression of a certain target genes identified herein. The compositions inhibit expression of the target gene when introduced into a tissue of the mammal. The methods include administering the compositions of the invention to a subject in need thereof in an amount effective to inhibit expression of a target gene in a cancerous tissue or organ.Type: ApplicationFiled: December 21, 2006Publication date: February 17, 2011Applicant: Intradigm CorporationInventors: Frank Y. Xie, Patrick Y. Lu, Martin C. Woodle, Yijia Liu
-
Patent number: 7786092Abstract: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.Type: GrantFiled: April 9, 2009Date of Patent: August 31, 2010Assignee: Intradigm CorporationInventors: Yijia Liu, Patrick Y. Lu, Martin C. Woodle, Frank Y. Xie
-
Patent number: 7781414Abstract: The present invention relates to methods for treating cancers by manipulating a target gene expression by up-regulation, silencing and/or down-regulation of the gene, such as EGFR-RP, TRA1, MFGE8, TNFSF13 and ZFP236, respectively. The methods are useful in treating cancers and/or inhibiting tumor growth by enhancing expression of a gene that is validated as a target such as ICT1030, for protein, peptide drug and gene therapy modalities; or by RNA interference to silence and/or down-regulate targets such as ICT1024, ICT1025 and ICT1031 and ICB1003 that are validated for antibody, small molecule and other inhibitor drug modalities.Type: GrantFiled: April 1, 2004Date of Patent: August 24, 2010Assignee: Intradigm CorporationInventors: Patrick Y. Lu, Frank Y. Xie, Martin C. Woodle, Yijia Liu, Quinn Q. Tang, Jun Xu
-
Patent number: 7723316Abstract: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.Type: GrantFiled: June 29, 2007Date of Patent: May 25, 2010Assignee: Intradigm CorporationInventors: Yijia Liu, Patrick Y. Lu, Martin C. Woodle, Frank Y. Xie
-
Publication number: 20100028848Abstract: This invention describes compositions and methods using siRNA to target various genes expressed in cells of transplanted organs or tissues and/or genes expressed in the host to improve the success of the transplantation.Type: ApplicationFiled: November 30, 2006Publication date: February 4, 2010Applicant: Intradigm CorporationInventors: Marie Denise Parker, Julian Roy Pratt, Yijia Liu, Yang Lu, Martin Woodle, Yuefeng Xie
-
Publication number: 20090247604Abstract: Compositions and methods for treating ocular disease are provided. Specifically, siRNA molecules and mixtures of siRNA molecules are provided that inhibit angiogenesis and/or neovascularization. The compositions and methods are suitable for treating ocular diseases associated with angiogenesis and/or neovascularization.Type: ApplicationFiled: February 7, 2005Publication date: October 1, 2009Applicant: Intradigm CorporationInventors: Quinn Tang, Patrick Y. Lu, Frank Y. Xie, Martin C. Woodle
-
Publication number: 20090227657Abstract: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.Type: ApplicationFiled: April 9, 2009Publication date: September 10, 2009Applicant: Intradigm CorporationInventors: Yijia Liu, Patrick Y. Lu, Martin C. Woodle, Frank Y. Xie
-
Patent number: 7534878Abstract: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.Type: GrantFiled: June 29, 2007Date of Patent: May 19, 2009Assignee: Intradigm CorporationInventors: Yijia Liu, Patrick Y. Lu, Martin C. Woodle, Frank Y. Xie
-
Publication number: 20080279920Abstract: The invention provides siRNA compositions that interfere with viral replication in respiratory viral infections, including respiratory syncytial virus and avian influenza A, including the H5N1 strain. The invention further provides uses of the siRNA compositions to inhibit expression of viral genes in respiratory virus-infected cells, and to uses in the treatment of respiratory virus infections in a subject. Generally the invention provides polynucleotide that includes a first nucleotide sequence of 15 to 30 bases that targets the genome of a respiratory syncytial virus or an influenza A virus, a complement thereof, a double stranded polynucleotide or a hairpin polynucleotide. Additionally the invention provides vectors, cells and pharmaceutical compositions containing siRNA sequences.Type: ApplicationFiled: November 4, 2005Publication date: November 13, 2008Applicant: Intradigm CorporationInventors: Qingquan Tang, Patrick Y. Lu, Frank Y. Xie, Martin C. Woodle, Bojian Zheng
-
Publication number: 20070203082Abstract: The present invention provides compositions and methods that are useful for the treatment of severe acute respiratory syndrome (SARS). More specifically, nucleic acid agents such as siRNA molecules and their analogues that target respiratory infections including SARS coronavirus and their methods of use are described, for clinical treatments of SARS, respiratory viral infections, for prevention and treatment of respiratory infections as needed for bio-defense, for treatment of respiratory diseases, and for discovery of therapeutic targets for respiratory diseases and infections.Type: ApplicationFiled: April 26, 2004Publication date: August 30, 2007Applicant: Intradigm CorporationInventors: Quinn Tang, Patrick Lu, Frank Xie, Yija Liu, Jun Xu, Martin Woodle
-
Publication number: 20060211637Abstract: Methods and compositions are provided for down regulation of target gene expression in vivo by RNA interference. The methods are useful for target discovery and validation of gene-based drug development, and for treatment of human diseases.Type: ApplicationFiled: August 6, 2003Publication date: September 21, 2006Applicant: Intradigm CorporationInventors: Puthupparampil Scaria, Martin Woodle, Patrick Lu, Qingquan Tang, Jun Xu, Frank Xie